These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22766670)

  • 21.
    Cicone F; Carideo L; Scaringi C; Arcella A; Giangaspero F; Scopinaro F; Minniti G
    Ann Nucl Med; 2019 Apr; 33(4):295-302. PubMed ID: 30607877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas.
    Watanabe T; Nakamura M; Kros JM; Burkhard C; Yonekawa Y; Kleihues P; Ohgaki H
    Acta Neuropathol; 2002 Mar; 103(3):267-75. PubMed ID: 11907807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of loss of heterozygosity with shorter survival in primary glioblastoma patients.
    Jesionek-Kupnicka D; Szybka M; Potemski P; Kulczycka-Wojdala D; Jaskólski D; Bieńkowski M; Skowroński W; Papierz W; Kordek R; Zawlik I
    Pol J Pathol; 2013 Dec; 64(4):268-75. PubMed ID: 24375041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?
    Fellah S; Caudal D; De Paula AM; Dory-Lautrec P; Figarella-Branger D; Chinot O; Metellus P; Cozzone PJ; Confort-Gouny S; Ghattas B; Callot V; Girard N
    AJNR Am J Neuroradiol; 2013 Jul; 34(7):1326-33. PubMed ID: 23221948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India.
    Jha P; Agarwal S; Pathak P; Srivastava A; Suri V; Sharma MC; Chosdol K; Srivastava T; Gupta D; Gupta A; Suri A; Sarkar C
    Cancer Genet Cytogenet; 2010 Apr; 198(2):126-34. PubMed ID: 20362227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of heterozygosity for loci on chromosome arms 1p and 10q in oligodendroglial tumors: relationship to outcome and chemosensitivity.
    Thiessen B; Maguire JA; McNeil K; Huntsman D; Martin MA; Horsman D
    J Neurooncol; 2003 Sep; 64(3):271-8. PubMed ID: 14558604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.
    Horbinski C; Nikiforova MN; Hobbs J; Bortoluzzi S; Cieply K; Dacic S; Hamilton RL
    J Neuropathol Exp Neurol; 2012 Jan; 71(1):73-82. PubMed ID: 22157622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular genetic alterations in glioblastomas with oligodendroglial component.
    Kraus JA; Lamszus K; Glesmann N; Beck M; Wolter M; Sabel M; Krex D; Klockgether T; Reifenberger G; Schlegel U
    Acta Neuropathol; 2001 Apr; 101(4):311-20. PubMed ID: 11355302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
    Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
    J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression.
    Ferrer-Luna R; Mata M; Núñez L; Calvar J; Dasí F; Arias E; Piquer J; Cerdá-Nicolás M; Taratuto AL; Sevlever G; Celda B; Martinetto H
    J Neurooncol; 2009 Dec; 95(3):343-354. PubMed ID: 19597701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Loss of heterozygosity of chromosome 1p/19q and p53 protein expression in oligodendroglioma].
    Xiong J; Liu Y; Li C; Zhu JJ; Ye ZR; Mao Y; Wang Y
    Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):445-50. PubMed ID: 19781190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic.
    Li YX; Shi Z; Aibaidula A; Chen H; Tang Q; Li KK; Chung NY; Chan DT; Poon WS; Mao Y; Wu J; Zhou L; Chan AK; Ng HK
    Oncotarget; 2016 Oct; 7(40):64615-64630. PubMed ID: 27556304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allelic status of 1p and 19q in oligodendrogliomas and glioblastomas: multiplex ligation-dependent probe amplification versus loss of heterozygosity.
    Franco-Hernández C; Martínez-Glez V; de Campos JM; Isla A; Vaquero J; Gutiérrez M; Casartelli C; Rey JA
    Cancer Genet Cytogenet; 2009 Apr; 190(2):93-6. PubMed ID: 19380026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
    Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ
    Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gliomas: association of histology and molecular genetic analysis of chromosomes 1p, 10q, and 19q.
    Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Sikorska B; Papierz W; Liberski PP
    Acta Neurobiol Exp (Wars); 2007; 67(2):103-12. PubMed ID: 17691218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma.
    Kraus JA; Koopmann J; Kaskel P; Maintz D; Brandner S; Schramm J; Louis DN; Wiestler OD; von Deimling A
    J Neuropathol Exp Neurol; 1995 Jan; 54(1):91-5. PubMed ID: 7815084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetically heterogeneous glioblastoma recurring with disappearance of 1p/19q losses: case report.
    Ito M; Wakabayashi T; Natsume A; Hatano H; Fujii M; Yoshida J
    Neurosurgery; 2007 Jul; 61(1):E168-9; discussion E169. PubMed ID: 17621007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
    Kaloshi G; Benouaich-Amiel A; Diakite F; Taillibert S; Lejeune J; Laigle-Donadey F; Renard MA; Iraqi W; Idbaih A; Paris S; Capelle L; Duffau H; Cornu P; Simon JM; Mokhtari K; Polivka M; Omuro A; Carpentier A; Sanson M; Delattre JY; Hoang-Xuan K
    Neurology; 2007 May; 68(21):1831-6. PubMed ID: 17515545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MRI Features Can Predict 1p/19q Status in Intracranial Gliomas.
    Lasocki A; Gaillard F; Gorelik A; Gonzales M
    AJNR Am J Neuroradiol; 2018 Apr; 39(4):687-692. PubMed ID: 29519793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.